Chemokine Receptor-6 Promotes B-1 Cell Trafficking to Perivascular Adipose Tissue, Local IgM Production and Atheroprotection

Prasad Srikakulapu1*, Aditi Upadhye2, Fabrizio Drago1, Heather M. Perry2, Sai Vineela Bontha1, Chantel McSkimming1, Melissa A. Marshall1, Angela M. Taylor2,3 and Coleen A. McNamara1,3*

1 Carter Immunology Center, University of Virginia, Charlottesville, VA, United States, 2 Cardiovascular Research Center, University of Virginia, Charlottesville, VA, United States, 3 Division of Cardiovascular Medicine, Department of Medicine, University of Virginia, Charlottesville, VA, United States

Chemokine receptor-6 (CCR6) mediates immune cell recruitment to inflammatory sites and has cell type-specific effects on diet-induced atherosclerosis in mice. Previously we showed that loss of CCR6 in B cells resulted in loss of B cell-mediated atheroprotection, although the B cell subtype mediating this effect was unknown. Perivascular adipose tissue (PVAT) harbors high numbers of B cells including atheroprotective IgM secreting B-1 cells. Production of IgM antibodies is a major mechanism whereby B-1 cells limit atherosclerosis development. Yet whether CCR6 regulates B-1 cell number and production of IgM in the PVAT is unknown. In this present study, flow cytometry experiments demonstrated that both B-1 and B-2 cells express CCR6, albeit at a higher frequency in B-2 cells in both humans and mice. Nevertheless, B-2 cell numbers in peritoneal cavity (PerC), spleen, bone marrow and PVAT were no different in ApoE−/−CCR6−/− compared to ApoE−/−CCR6+/+ mice. In contrast, the numbers of atheroprotective IgM secreting B-1 cells were significantly lower in the PVAT of ApoE−/−CCR6−/− compared to ApoE−/−CCR6+/+ mice. Surprisingly, adoptive transfer (AT) of CD43− splenic B cells into B cell-deficient µMT−/−ApoE−/− mice repopulated the PerC with B-1 and B-2 cells and reduced atherosclerosis when transferred into ApoE−/−CCR6+/+slgM−/− mice only when those cells expressed both CCR6 and slgM. CCR6 expression on circulating human B cells in subjects with a high level of atherosclerosis in their coronary arteries was lower only in the putative human B-1 cells. These results provide evidence that B-1 cell CCR6 expression enhances B-1 cell number and IgM secretion in PVAT to provide atheroprotection in mice and suggest potential human relevance to our murine findings.

Keywords: B-1 cells, IgM, CCR6, atherosclerosis, inflammation, perivascular adipose tissue
INTRODUCTION

Atherosclerosis is well-recognized as a chronic inflammatory disease of arteries and plaque rupture is the primary underlying cause of cardiovascular events. Atherosclerosis develops when low density lipoproteins (LDL) enter the subendothelial layer of the artery wall and become oxidized. Products of oxidized lipids are highly reactive and modify self-molecules, thereby generating oxidation-specific epitopes (OSE) that are recognized by receptors of the immune system, including scavenger receptors on macrophages leading to foam cell formation. Oxidized LDL and foam cells promote inflammatory cytokine production and induce the expression of cell adhesion molecules on endothelial cells. Surface adhesion molecule expression recruits inflammatory cells such as monocytes, T cells, natural killer cells, natural killer T cells, and dendritic cells into the subendothelial layer, developing lesion formation (1–3).

B cells play a major role in the regulation of atherosclerosis, and their effects are subset and context-dependent. B-1 B cells attenuate and B-2 B cells aggravate atherosclerosis (4–9). Treatments that deplete predominantly B-2 cells such as anti-CD20 monoclonal antibody and B-cell activating factor receptor (BAFFR) deficiency attenuated atherosclerosis development in apolipoprotein-E deficient (ApoE−/−) and low-density lipoprotein receptor deficient (LdlR−/−) mice maintained on Western diet (WD) (5, 6, 8, 9). In contrast, IgM secreting B-1 cells have been shown to be atheroprotective (4, 7). B-1 cells, which are the major source for circulatory IgM (10, 11) and attenuate atherosclerosis (4, 7, 8), can be further divided into two sister populations: B-1a and B-1b. IgM can block the uptake of oxidized LDL by macrophages (12) and, immunization to boost IgM to OSE resulted in atheroprotection (13).

Perivascular adipose tissue (PVAT) directly contacts the artery adventitia and has a role in the regulation of atherosclerosis. Data demonstrates that PVAT adjacent to atherosclerotic human blood vessels is more inflamed than PVAT adjacent to non-diseased vessel segments (14). Adipocytes in PVAT secrete both pro inflammatory and anti-inflammatory cytokines (15). We have recently shown that the PVAT harbors both B-1 and B-2 B cell subtypes in young ApoE−/− mice and these local B-1 cells can be induced to proliferate by cytokines (16) and produce atheroprotective IgM antibodies locally (17). However, the mechanism involved in B-1 cell trafficking to PVAT is not known.

Chemokines and chemokine receptors regulate immune cell trafficking and may be key targets or molecules to control homing of immune cells to sites of human disease (18). C-C chemokine receptor 6 (CCR6) is a G protein-coupled receptor expressed on different immune cell types such as macrophages, immature dendritic cells, T and B-lymphocytes (19). CCR6 and its ligand CCL20 have emerged as important regulators of atherosclerosis (18, 20–22). Global deletion of Ccr6 in ApoE−/− and LdlR−/− mice resulted in decreased Ly6Chigh monocyte exit from the bone marrow, less recruitment of pro-atherogenic macrophages to lesions and attenuated atherosclerosis (20, 22). In human atherosclerosis, the expression of CCR6 and CCL20 in atherosclerotic lesions in the coronary and carotid arteries has been reported. In addition, CCL20 expression is positively correlated with DC numbers in the shoulder regions of the lesion (23), and this DC derived CCL20 may attract CCR6 expressing immune cells into the lesion. Also, circulating levels of CCL20 is significantly increased in hypercholesterolemic patients and LDL stimulated vascular smooth muscle cells express CCL20 and promote human lymphocyte migration (18), implicating a role for the CCR6-CCL20 axis in atherosclerosis development. Previous data from our lab demonstrated that CCR6 regulated aortic homing of CD43− splenocytes (B cells) and diet induced atheroprotection in B cell deficient (μMT−/−) mice (21). In general, CD43− splenocytes are thought to be B-2 cells which are considered atherogenic. Thus, it is not clear how the aortic homing of these CD43− splenocytes provides atheroprotection. B cell subsets may have distinct functions in the local PVAT compared to peripheral sites, and atheroprotection may depend on the ability of B cells to home to athero-prone aortic sites (21). Taken together, the results suggest that CCR6 may be a pro- or anti-atherogenic chemokine receptor depending on the cell type in which it is expressed and underscore a need to better understand the role of CCR6 in B cells.

In this current study, we provide the first evidence of a B-1 cell specific function for CCR6 in regulating B-1 numbers and IgM production in PVAT. We demonstrate that atheroprotective effects of CD43− splenocytes in ApoE−/−/slgM−/− mice are CCR6-dependent and require the cells to be capable of secreting IgM implicating PVAT trafficking of B-1 cells as a potentially important atheroprotective mechanism. Further, we demonstrate that in humans, expression of CCR6 on a putative B-1 cell population (24) was significantly reduced in patients with a high degree of coronary artery disease (CAD) underscoring the potential clinical relevance of our findings and suggesting that B-1 cell-specific augmentation of CCR6 expression may be a potential therapeutic approach.

MATERIALS AND METHODS

Animals

All animal protocols were approved by the Animal Care and Use Committee at the University of Virginia. Apolipoprotein E deficient (ApoE−/−) mice, B cell deficient (μMT−/−) mice, and chemokine receptor six deficient (CCR6−/−) were purchased from Jackson Laboratory and maintained in our animal facility (University of Virginia). μMT−/− and CCR6−/− mice were bred to the ApoE−/− line to develop ApoE−/−μMT−/− mice, and chemokine receptor six deficient (CCR6−/−) were purchased from Jackson Laboratory and maintained in our animal facility (University of Virginia). μMT−/− and CCR6−/− mice were bred to the ApoE−/− line to develop ApoE−/−μMT−/− and ApoE−/−CCR6−/− knockout mice. Generated ApoE−/−CCR6−/− mice and setup heterozygous breeders (ApoE−/−CCR6+/− x ApoE−/−CCR6+/−) to generate ApoE−/−CCR6−/+ and their littermate controls ApoE−/−CCR6−/−. All purchased mice were on C57BL/6J background and those bred were backcrossed to C57BL/6J mice for 10 generations. sIgM−/− mice were kindly provided by Dr. Peter Lobo (University of Virginia) and crossed to ApoE−/− mice to generate ApoE−/−sIgM−/− mice. All mice were given water ad libitum and standard chow diet (Tekland, 7012). Mice were euthanized with CO2 inhalation. Young (8–10 weeks) male mice were used for all experiments except for atherosclerosis studies. For atherosclerosis studies,
ApoE−/− mice were maintained on WD (42% fat, Tekland, 88137) for 12 weeks.

**Human Samples**

Patients (n = 118) were recruited for study through the Cardiac Catheterization laboratory at the University of Virginia as previously described (25). All participants provided written informed consent prior to enrollment, and the study was approved by the Human IRB Committee at UVA. A total of 118 patients presenting for a medically indicated diagnostic cardiac catheterization were enrolled if they met inclusion criteria. Participants were excluded if they had: any acute illness, type 1 diabetes, current acute coronary syndrome, autoimmune disease or on immunosuppressive therapy, prior organ transplantation, anemia, pregnancy, or HIV infection. No patient was on anticoagulation or had deep vein thrombosis or pulmonary embolism. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood for flow cytometry experiments. Isolation of PBMC's from human peripheral blood was performed by RBC lysis in whole blood, and the purified PBMCs were used for flow staining. List of antibodies for cell surface markers (name of the clone) for human flow cytometry: CD3 (SK7 or UCHT1), CD20 (2H7), CD4 (RPA-T4), CD8 (RPA-T8), CD14 (61D3), CCR6 (11A9), CD27 (M-T271) and CD43 (1G10) were purchased from eBioscience and BD Bioscience. Live/Dead staining (Invitrogen). Cells were run on CyAN ADP (Beckman Coulter) and Attune NxT flow cytometer (Invitrogen). Data were analyzed with FlowJo 10 software.

**Adoptive Transfer Experiments**

PerC cells were isolated from ApoE−/− mice and stained for FACSorting (InFlux sorter). Cells were stained with fluorescence labeled antibodies against CD19 (1D3), B220 (RA3-6B2), CD23 (B3B4), IgD (11-26c) and CD5 (53-7.3), and live cells were gated for DAPI− population. Two hundred thousand of FACSorted B-1 cells were adoptively transferred into 8–10 week old ApoE−/−IgM−/− mice via intraperitoneal injection. For CD43− splenocyte isolation, spleens were harvested from 10–12 week old donor mice and B cells were isolated using MACS anti-CD43 microbeads (Miltenyi Biotec) as per the manufacturer's protocol. The purity of representative samples was analyzed by flow cytometry and found to be >97%. Either 30 × 10⁶ or 60 × 10⁶ B cells were resuspended in 200 µl of PBS and adoptively transferred via tail vein injection to 8–10 week old recipients.

**Enzyme-Linked ImmunoSpot Assay**

Single cell suspensions of PVAT, spleen and BM were prepared as described above in the flow cytometry section. ELISpOT was performed as previously described (4, 17, 27). Sterile MultiScreen IP-Plates (Millipore, MSIPS54510) were used for the assay according to manufacturer's protocol. Wells were coated with unlabeled goat anti-mouse IgM antibody (10 µg/ml; Southern Biotech) and incubated overnight at 4°C. The next day, antibody solution was decanted, membrane was washed with PBS and then blocked with RPMI 1640+10% FCS for 2 h at 37°C. A suspension of 1 × 10⁶ cells/ml was prepared in ice cold culture media for spleen and BM from which 100,000 cells were plated for each of the sample as starting concentration and then were serially diluted in subsequent wells. For PVAT samples, resuspended in 250 µl culture media and were used as starting concentration from which serial dilutions in subsequent wells were prepared. The plate was incubated overnight at 37°C in a cell culture incubator (5% CO₂). Cells were decanted, washed (PBS+0.01% tween-20) and incubated with biotin-labeled goat anti-mouse IgM antibody (1:500 dilution) (Southern Biotech) for 2 h in a cell culture incubator. After washing, cells were incubated for 30 min at room temperature in streptavidin alkaline phosphatase (Abcam). Again, following washing BCIP/NBT (Gene Tex Inc.)
was added and incubated until spots became visible. Each spot on the membrane indicated an antibody secreting cell. Spots were counted manually.

**Enzyme-Linked Immunosorbent Assay**

Plasma or serum samples were collected from mice and circulatory total IgM and IgG levels were quantified by ELISA as published before (28). Total IgE ELISA was performed according to manufacturer’s guidelines (BioLegend). For MDA epitope specific IgM and IgG ELISA, we used Peptide mimotope for malondialdehyde (MDA) epitope (P2 peptide-biotin) (Peptide 2.0) as a capture antigen (29). Briefly, 96 well microtiter plates (Corning) were incubated at 4°C overnight with capture unlabeled IgM or IgG diluted in coating buffer (0.1 M disodium phosphate pH 9.0). Plates were blocked (PBS containing 0.5% BSA, 0.1% TWEEN-20, and 0.01% NaN3), incubated with samples, and then treated with IgM detection antibody conjugated to alkaline phosphatase for 2h at room temperature. Detection antibodies and dilutions used: murine IgM-AP and murine IgG-AP (Southern Biotech). Plates were then developed with pNPP solution (Southern Biotech) for 30–60 min and read at 405 nm using a SpectraMax 190 ( Molecular Devices). IgM concentration was determined through a standard curve of purified immunoglobulin (Southern Biotech) using a range of 0.098–200 ng/ml. All dilutions were determined through careful titration, and only values within the range of standard curves with readings at least 3-fold higher than negative controls were used.

**Enface Staining**

Aortas were harvested carefully as previously described (17). Aortas were opened longitudinally, fixed in 4% formaldehyde, pinned, and stained with Sudan IV (Sigma). Aortas were imaged with a Nikon D70 DSLR camera and enface lesion area was quantified using ImagePro Plus 7.0 software.

**Statistics**

Student’s t-test was used for analyzing data with normal distribution and equal variance. For data sets with non-normal distribution, Wilcoxon rank-sum test was used. Similarly, a non-parametric test (Spearman’s correlation) was used to correlate data that was not normally distributed. One-way Anova with multiple comparison was used when compared multiple groups. Results are displayed containing all replicated experiments, and values shown are mean ± SEM. Data were analyzed using Prism 8 (GraphPad Software, Inc) and SAS (SAS version 9.4).

**RESULTS**

**A Higher Frequency of CCR6+ B-1 Cells in Tissue Compartments That Support Antibody Production Compared to Their Homeostatic Niche**

To compare the expression levels of CCR6 in B-1 and B-2 cells, we performed flow cytometry on isolated cells from various compartments and measured the frequency of CCR6+ B-1 and B-2 cells from atherosclerosis prone chow fed ApoE−/− mice. **Figure 1A** depicts the gating strategy for identifying B-1 and B-2 cells and a representative histogram showing CCR6 expression relative to an FMO control. Quantification of the frequency of CCR6+ B-1 and B-2 cells in different tissue compartments revealed that both B-1 and B-2 cells express CCR6. Interestingly, the frequency of CCR6+ B-1 cells was significantly higher in antibody secreting tissue compartments such as spleen, BM and PVAT compared to the primary B-1 cell niche, PerC (**Figure 1B**). However, despite a higher frequency of CCR6+ cells, there was no such difference observed in B-2 cells (**Figure 1C**). This data suggests that CCR6 may be important for B-1 cell recruitment to antibody secreting regions.

**CCR6 Deficiency Reduces B-1 Cell Numbers in PVAT**

Previous data from our lab clearly showed that CCR6 regulates B cell migration to aorta and provides atheroprotection (21) and that PVAT harbors higher numbers of atheroprotective IgM-producing B-1 cells than the aorta itself (17). To determine the effect of CCR6 deficiency on B cell subset distribution in PVAT and other tissue compartments in atherosclerosis-prone mice at homeostasis, flow cytometry and ELISPOT experiments were performed in young ApoE−/−/CCR6+/- and ApoE−/−/CCR6−/− littermate control mice (10 weeks old) fed normal Chow diet. There was no difference in total body weight (**Figure 2A**) and PVAT weight (**Figure 2B**). PVAT collected from the aortic arch to the iliac bifurcation was carefully dissected and flow cytometry was performed to analyze B-1 and B-2 cells (**Figure 2C**). Flow cytometry data revealed B-1 cell numbers but not B-2 cell numbers were significantly reduced in PVAT of ApoE−/−/CCR6−/− mice compared to ApoE−/−/CCR6+/+ mice (**Figure 2D**). ELISPOT data demonstrate that total IgM secreting B cells were reduced in PVAT in ApoE−/−/CCR6−/− mice compared to ApoE−/−/CCR6+/+ mice (**Figure 2E**). Intriguingly, there was no difference of B-1 and B-2 cell numbers in PerC, spleen and BM compartments between ApoE−/−/CCR6+/+ and ApoE−/−/CCR6−/− mice (**Figures 2F–H**). Correspondingly, there was no difference in total IgM secreting B cells in spleen and BM ApoE−/−/CCR6+/+ and ApoE−/−/CCR6−/− mice (**Figure 2I**), and there was no difference in plasma total IgM levels between ApoE−/−/CCR6+/+ and ApoE−/−/CCR6−/− mice as well (**Figure 2J**).

**CD43+ Splenocytes (B cells) Can Repopulate/Establish B-1 Cell Compartment**

To understand whether B-1 cells can migrate, survive and produce IgM in PVAT, FACS-sorted B-1 cells (2 × 10⁵) were adoptively transferred into secretory IgM (sIgM−/-) deficient ApoE−/− mice via i.p injection. After 7 weeks of the adoptive transfer, plasma IgM levels were measured by ELISA at different time points. The plasma IgM levels were boosted after 1st week of the B-1 cell transfer compared to PBS injected ApoE−/−/sIgM−/- mice. However, secreted IgM levels in the plasma eventually dropped down to baseline within 4 weeks of transfer (**Supplementary Figure 1**). Flow cytometry analysis confirmed non-survival of adoptively transferred B-1 cells in ApoE−/−/sIgM−/- mice after 2 weeks (data not shown).
FIGURE 1 | Frequency of CCR6⁺ B-1 cells was higher in antibody secreting tissue compartments in mice. (A) Gating strategy for B-1 and B-2 cells in PVAT and representative histogram of CCR6 expression. Gray line represents FMO for CCR6 and filled blue line represents B-1 or filled orange line represents B-2 cells in flow cytometry histogram plots (B) percentage of CCR6⁺ B-1 cells from total B-1 cells and (C) percentage of CCR6⁺ B-2 cells from total B-2 cells in different tissue compartments. Results are represented in mean ± SEM, Performed One-way ANOVA with multiple comparisons. *p < 0.05 and **p < 0.01. n = 6–8 mice/group and each dot represents individual mouse.

Since survival of B-1 cells alone is not possible for long-term experiment we sought out an alternative approach. We previously showed that adoptive transfer of CD43⁻ splenocytes (B cells) into B cell deficient mice provided atheroprotection compared to vehicle (PBS) injected mice (21). Yet, CD43⁻ splenocytes have been thought to represent B-2 cells which are considered atherogenic (5, 6, 8, 9) and B-1 cells are CD43⁺ (10, 17, 30). However, this paradigm did not explain how CD43⁻ B cell transfer provided atheroprotection in B cell deficient ApoE⁻/⁻/µMT⁻/⁻ mice (21). We analyzed CD43 expression in B cell compartments by doing flow cytometry in ApoE⁻/⁻ mice. Flow data clearly demonstrate that the majority (>95%) of B-2 cells and ~10-15% of B-1a were CD43⁻ in both PerC and spleen. Interestingly, ~60% of B-1b cells were CD43⁻ in both PerC and spleen (Figure 3A). The data suggested that the CD43⁻ splenocyte population contains remnant B-1 cells, in particular B-1b cells. Next, to address whether CD43⁻ splenocytes can repopulate B-1 cells in recipient mice, MACS purified CD43⁻ splenocytes (B cells; 60 x 10⁶) were adoptively transferred via tail vein injection into ApoE⁻/⁻/µMT⁻/⁻ mice and maintained on WD for 16 weeks (Figure 3B). Interestingly, flow cytometry data clearly demonstrated that adoptively transferred CD43⁻ splenocytes could repopulate both B-1 and B-2 cells in PerC and spleen respectively in ApoE⁻/⁻/µMT⁻/⁻ mice. In addition, these B-1 cells contain both B-1a and B-1b subsets (Figure 3C). Also, flow cytometry data confirmed that the purity of CD43⁻ splenocytes after MACS separation was >97%. MACS separation significantly reduced CD43⁺ B-1 compartment (~90%) (Supplementary Figure 2). It is also possible that the remnant CD43⁺ cells could also repopulate. We next wanted to determine if these CD43⁻ splenocytes in the absence of CCR6 can provide IgM mediated atheroprotection.

Atheroprotection by IgM Secreting B Cells Is CCR6 Dependent

To determine the effect of CCR6 on IgM secreting B cell mediated atheroprotection, 30 x 10⁶ CD43⁻ splenocytes from ApoE⁻/⁻/CCR6⁺/⁺/sIgM⁺/⁺ or ApoE⁻/⁻/CCR6⁻/⁻/sIgM⁺/⁺ or ApoE⁻/⁻/CCR6⁺/⁺/sIgM⁻/⁻ or PBS (control) mice were adoptively transferred via tail vein injection into ApoE⁻/⁻/CCR6⁺/⁺/sIgM⁻/⁻ mice following which the recipients were fed WD for 12 weeks (Figure 4A). Cholesterol levels were no different between the groups after 12 weeks of WD (Supplementary Figure 3). We started by determining the
effect of CCR6 on IgM production. We measured circulatory IgM levels by ELISA. Interestingly, circulatory IgM levels were significantly higher in mice that received B cells from ApoE<sup>−/−</sup>CCR6<sup>+/−</sup> sIgM<sup>+/−</sup> mice but not in mice that received CD43<sup>−</sup> splenocytes from ApoE<sup>−/−</sup>CCR6<sup>−/−</sup> sIgM<sup>+/−</sup> mice compared to PBS (control) mice. While these differences are detectable in sIgM<sup>−/−</sup> mice, these levels are far lower than in WT mice, likely obscuring this small but significant difference. As expected, there was no difference of circulatory IgM levels in mice that received CD43<sup>−</sup> splenocytes from ApoE<sup>−/−</sup>CCR6<sup>−/−</sup> sIgM<sup>+/−</sup> mice compared to PBS (control) mice (Figure 4B). A trend of lower levels of circulatory total IgG, IgE and MDA mimotope specific IgG were observed between PBS (control) and B cell recipient groups (Supplementary Figure 4).

Next, we wanted to measure atherosclerosis levels. The percentage of enface lesion area was quantified in aortas by Sudan IV staining (Figure 4D). Intriguingly, atherosclerosis levels were significantly reduced in mice that received CD43<sup>−</sup> splenocytes from ApoE<sup>−/−</sup>CCR6<sup>+/−</sup> sIgM<sup>+/−</sup> mice compared to those that received PBS (control). There was no difference in atherosclerosis levels in mice that received CD43<sup>−</sup> splenocytes from ApoE<sup>−/−</sup>CCR6<sup>−/−</sup> sIgM<sup>+/−</sup> or ApoE<sup>−/−</sup>CCR6<sup>−/−</sup> sIgM<sup>−/−</sup> compared to PBS (control). Moreover, the CD43<sup>−</sup> splenocytes from ApoE<sup>−/−</sup>CCR6<sup>+/−</sup> mice attenuated atherosclerosis only when they were capable of secreting IgM (Figure 4E).
Expression of CCR6 on Human Putative B-1 Cells (CD20^+ CD27^+ CD43^+) Was Significantly Lower in Patients With High CAD Severity Scores

Next, to examine CCR6 expression on circulatory B cell subsets including putative B-1 cells in humans, PBMCs were collected from patients presenting for a medically indicated coronary angiography CAD assessment. Flow cytometry was performed on PBMCs with antibodies that allowed quantification of CCR6 on B cells, T cells and monocytes. Consistent with previous reports (31–34), all B cells express CCR6 and ~27% of CD4^+ T cells and ~10% of CD8^+ T cells express CCR6. However, circulating human monocytes do not express CCR6 (Supplementary Figure 5), despite CCR6 on monocytes being implicated in atherosclerosis in murine models (20, 22). Next to understand the CCR6 expression levels on B-1 cells, total CD20^+ B cells were gated for naïve, memory and B-1 cells by using CD43 and CD27 (Figure 5A) (24, 35). The frequency of CCR6^+ B-1 cells (Figure 5B) and GM mean of CCR6 expression on CD20^+ CD27^+ CD43^+ B-1 cells (Figure 5C) was lower compared to naïve and memory B cells in circulation.

To determine whether expression of CCR6 on circulating B cell subsets was associated with the severity of CAD, we utilized the well-established gensini scoring system (GS) as outlined in the section Methods. GM of CCR6 on total B cells and B cell subsets was quantified in low GS and high GS patients. There was no difference in age, gender, diabetes and hypertension between GS low and high groups (Supplementary Table 1). There was no difference of GM of CCR6 on total B cells, naïve and memory B cells (Figures 5D–F). Interestingly, GM of CCR6 on B-1 cells was significantly lower in patients with high GS (Figure 5G), suggesting that CCR6 expression on human B-1 cells may protect from development of severe coronary artery atherosclerosis.

DISCUSSION

The abundance of atheroprotective B-1 cells in the PVAT has been previously reported by our group (17). However, the mechanism and the role of chemokine receptors in their homing to the PVAT has not been demonstrated. Chemokine receptors are important for the recruitment or migration of immune cells to lymphoid tissues and inflammatory sites to regulate the immune responses. CCR6 is expressed on different leukocyte populations, such as immature dendritic cells (36), B cells (32, 33), T cells (34), NKT cells (37). Previous studies of CCR6 on B cells mainly focused on mature adaptive B-2 cells. Our study is the first to identify a role for CCR6 in regulating B-1 cell number and IgM production in PVAT and a CCR6-dependent IgM-mediated inhibition of diet-induced atherosclerosis.
Two decades ago, an elegant study was published by Krzysiek et al., where they demonstrated the functional role of CCR6 expression during B cell development and antigen mediated B cell differentiation in humans. CCR6 is not expressed during early B cell development in the BM. However, it is expressed later by all mature B cells in the BM, peripheral blood and umbilical cord blood. Eventually, mature B cells lose their CCR6 expression upon activation via B cell receptor signaling and entering into germinal center reactions and terminally differentiating into antibody secreting plasma cells in secondary lymphoid organs. Interestingly, CCR6 is re-expressed once these germinal center B cells differentiate into memory B cells (33) and also these cells show increased chemotactic response to the CCR6 ligand, CCL20 (38). This data suggests that CCR6 expression is restricted to functionally mature B cells capable of responding to antigen challenge. Another study demonstrated that CCR6 expression was important for the migration of memory B cells to the mucosal tissue to produce IgA against intestinal microbial antigens (39). CCR6 is necessary for positioning of memory B cells in spleen to mount recall responses to the same antigen (40) and is thus involved in the regulation of B cell development and their function, particularly, mature activated B-2 cells.

Consistent with previous reports (31, 33), our flow cytometry data in human PBMCs showed that almost all B cells, a small percentage of T cells, and none of the monocytes in circulation express CCR6. In addition, our human data shows that the frequency of CCR6+ B-1 cells was significantly lower compared to naive, and memory B cells in circulation. Though the frequency of CCR6+ B-1 cells was lower than B-2 cells in all tissue compartments in the murine system at homeostasis, the frequency of CCR6+ B-1 cells in antibody secreting tissue compartments such as the spleen, BM and PVAT was higher compared to their primary homeostatic niche (PerC). Further, in the absence of CCR6 (ApoE−/−CCR6−/−) there were significantly fewer IgM secreting B-1 cells in PVAT but not in PerC, spleen and BM. This data suggests that CCR6 expression on B-1 cells may play an important role in B-1 recruitment to PVAT to attenuate disease progression.

Our murine data showed that the number of atheroprotective IgM secreting B-1 cells were significantly reduced in PVAT of ApoE−/−CCR6−/− compared to control group at homeostasis. However, there is no difference in plasma IgM levels between ApoE−/−CCR6+/+ and ApoE−/−CCR6−/−. This may be due to lack of differences in B-1 cell numbers in the major IgM
producing sites such as spleen and BM. Similar to the role of chemokine receptors such as CXCR5, which is important for recruitment/migration of B-1 cells to their primary niches such as PerC and omental fat (41) and CXCR4 in regulation of atheroprotective IgM secreting B-1a cell recruitment to bone marrow (35), our findings provide evidence that CCR6 is important for B-1 cell recruitment to PVAT. The atheroprotective effect is likely due to local (PVAT) IgM secretion, not detected by changes in plasma levels.

Murine studies demonstrate that CCR6 on monocytes is important for their recruitment to aorta to aggravate atherosclerosis. In CCR6 deficient ApoE−/− mice atherosclerosis levels were significantly reduced compared to littermate controls (ApoE−/−/CCR6+/+) after WD feeding which can be attributed to reduction in BM derived Ly6C hi inflammatory monocyte subtype in circulation and thereby reduction in macrophage numbers in atherosclerotic lesions (20). A similar finding was reported in CCR6 deficient LdlR−/− mice where atherosclerosis levels were significantly reduced in aorta and aortic sinus via reduction in the numbers of Gr-1 hi and Gr-1 low monocytes in circulation followed by reduction in accumulation of macrophage numbers in the lesions when compared to LdlR−/−/CCR6+/+ control mice. Contrary to the changes observed in monocyte subset numbers, there was no difference in frequencies of Th1, Th17 and regulatory T cells locally and systemically between LdlR−/−/CCR6−/− and LdlR−/−/CCR6+/+ mice (22). Consistent with our human data on CCR6 expression on human leukocytes, initially, CCR6 was not thought to be expressed on human monocytes (42). However, studies have shown a substantial increase in CCR6 expression on monocytes during inflammatory conditions. Around 3% of circulating monocytes expressed CCR6 in blood and synovial fluid from rheumatoid arthritis patients and these monocytes responded to CCL20 chemotaxis in vitro (31). This suggests that chemokine receptor expression may increase on leukocytes during inflammatory conditions and promote recruitment to sites of inflammation in humans.

While global deletion of CCR6 conferred atheroprotection, previous studies of the role of CCR6 on B cells demonstrate an atheroprotective effect. Adoptive transfer of CD43− splenocytes from CCR6+/+ but not CCR6−/− donors showed increased recruitment of B cells to the aorta (taken together with PVAT) and significantly reduced diet induced atherogenesis in µMT−/− recipients (21). Also, upon comparing aorta and PVAT separately, we have shown that PVAT and not aorta has more B cells (17). This suggests that CCR6 is involved in B cell homing to PVAT and in conferring B cell-mediated atheroprotection.

**FIGURE 5** | Percentage of CCR6+ and GM of CCR6 on human circulating B cell subtype with lower CCR6 GM on putative human B-1 cells from subjects with high CAD severity score. (A) gating strategy for circulating B cell subsets (naive, memory and B-1 B cells) by using CD43 and CD27. (B) percentage of CCR6+ B cell subsets from total B cells and (C) GM of CCR6 expression on B cell subsets. Results are shown in mean ± SEM, paired t-test was performed. ****p < 0.0001. (D–G) GM of CCR6 on total B cells (D), naïve (E), memory (F) and B-1 B cells (G) in subjects with low and high Gensini scores. Results are shown in mean ± SEM, Mann-Whitney t-test was performed. *p < 0.05.
Adoptive transfer of FACS sorted B-1 cells alone do not survive long-term in ApoE<sup>−/−</sup> slgM<sup>−/−</sup> recipients. We therefore took the approach of transferring CD43<sup>−</sup> splenocytes as per our previous publication (21). Notably, although the percentage of splenic B-1 cells that are CD43<sup>−</sup> is lower than the percentage of CD43<sup>−</sup> B-2 cells, 10-15% of B-1a and 60-70% of B-1b cells in both PerC and spleen are CD43<sup>−</sup> (Figure 3A). These B-1 cells together with few remnant CD43<sup>+</sup> B-1 cells could re-populate during the 16 weeks of time prior to the end of our study due to their self-renewing capacity. Our current study suggests that this re-population of atheroprotective IgM secreting B-1 cells led to atheroprotection.

In this current study we performed the adoptive transfer of CD43<sup>−</sup> splenocytes into slgM deficient mice that have endogenous B cells unlike the uMT<sup>−/−</sup> mice in our previous study (21). slgM deficiency increases marginal zone B cells and reduces follicular B cells (43, 44). Though marginal zone B cells are primarily involved in providing protection from blood borne pathogens (45). However, these B-1 cells are also involved in atheroprotection by reducing follicular T helper cell development via programmed death ligand-1 signaling (46). These follicular T helper cells are important for differentiation of follicular B cells into germinal center B cells followed by antigen specific antibody producing B cells. IgG is a major antibody type secreted by B cells that undergo germinal center reactions. With regards to follicular B cells, it has been reported that slgM<sup>−/−</sup> mice display increased B cell receptor signaling that results in abnormal B cell development followed by reduced follicular B cell numbers (44). This condition leads to increased circulatory pathogenic IgE levels in circulation and aggravated atherosclerosis in atherogenic diet fed Ldlr<sup>−/−</sup> slgM<sup>−/−</sup> mice compared to control group (47). None of the ApoE<sup>−/−</sup> slgM<sup>−/−</sup> recipient mice in our study regardless of genotype of the donor cells had differences in circulatory total IgG and IgE antibody levels arguing against this mechanism for the atheroprotection seen in our study.

We have previously shown that slgM deficiency aggravates atherosclerosis in mice (48) and local PVAT mRNA levels of proinflammatory cytokines like INFγ and TNFα in slgM<sup>−/−</sup> mice are significantly higher compared to littermate controls (unpublished data). This supports the role of locally produced IgM in regulation of PVAT inflammation. This data is consistent with our previous report that show that CCR6 deficiency significantly reduced B cell recruitment to aorta and adoptive transfer of B cells from CCR6<sup>−/−</sup> mice no longer provided atheroprotection (21). CCR6 is thus important for B-1 cell recruitment and local IgM production in the PVAT. B-1 cell derived IgM in fact could influence the disease levels by altering the local environment in the PVAT of mice either by reducing inflammatory cytokine production (TNFα and MCP-1) from M1 type macrophages in adipose tissue (28), or by mediating opsonization of apoptotic cells and accelerating their clearance by phagocytic cells (49, 50). CCR6, thus, may regulate B-1 cell recruitment to PVAT and control local inflammatory responses.
by secreting IgM and thereby its use in development of cell-based therapeutics could help in modulation of the disease (Figure 6).

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by University of Virginia Human Investigation Committee. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by University of Virginia Animal Care and Use Committee.

**AUTHOR CONTRIBUTIONS**

PS designed and performed the experiments, acquired and analyzed the data, prepared figures, and wrote the manuscript. AU, HMP, MAM, and CM performed the experiments. FD analyzed human data. SVB edited scientific content in the manuscript. AMT acquired coronary angiography data. CAM designed the experiments and edited the manuscript. Each author contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by National Heart, Lung, and Blood Institute Grants R01-HL-136098, R01-HL-136275, and R01-HL-107490 (CAM), American Heart Association Career Development Award (18CDA34110392) to PS. AHA predoctoral fellowship 16PRE30300002 and training grant 5T32AI070496-20 to AU and training grant T32GM07055-35 to HMP.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.636013/full#supplementary-material

**REFERENCES**

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. *Nat Immunol.* (2011) 12:204–12. doi: 10.1038/ni.2001

2. Wigren M, Nilsson J, Kolbus D. Lymphocytes in atherosclerosis. *Clin Chim Acta.* (2012) 9:413:1562–8. doi: 10.1016/j.cca.2012.04.031

3. Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. *Nat Rev Immunol.* (2016) 16:485–97. doi: 10.1038/nri.2016.63

4. Rosenfeld SM, Perry HM, Gonen A, Prohaska TA, Srikakulapu P, Grewal S, et al. B-1b cells secrete atheroprotective IgM and attenuate atherosclerosis. *Circ Res.* (2015) 117:e228–39. doi: 10.1161/CIRCRESAHA.115.306044

5. Ait-Outella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, et al. CD43 depletion reduces the development of atherosclerosis in mice. *J Exp Med.* (2010) 207:1579–87. doi: 10.1084/jem.20100155

6. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. *PLoS ONE.* (2012) 7:e29371. doi: 10.1371/journal.pone.0029371

7. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, et al. BAFF receptor deficiency reduces the development of atherosclerosis in mice-brief report. *Arterioscler Thromb Vasc Biol.* (2012) 32:1573–6. doi: 10.1161/ATVBAHA.111.248942

8. Choi YS, Dieter JA, Rothaeusler K, Luo Z, Baumgarth N. B-1 cells in the bone marrow are a significant source of natural IgM. *Eur J Immunol.* (2016) 46:120-9. doi: 10.1002/eji.201441890

9. Holodick NE, Vizconde T, Rothstein TL. Splenic B-1a cells expressing CD138 spontaneously secrete large amounts of immunoglobulin in naïve mice. *Front Immunol.* (2014) 5:129. doi: 10.3389/fimmu.2014.00129

10. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. *J Clin Invest.* (1999) 103:117–28. doi: 10.1172/JC11553
13. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized lDL. Nat Med. (2003) 9:736–43. doi: 10.1038/nm876

14. Henrichot E, Juge-Auby CE, Permin A, Pache JC, Velebit V, Dayer JM, et al. Production of Chemokines by Perivascular Adipose Tissue: A Role in the Pathogenesis of Atherosclerosis? Arterioscler Thromb Vasc Biol. (2005) 25:2594–9. doi: 10.1161/ATVBAHA.104.305235

15. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, Weintrab NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol. (2010) 10:191–6. doi: 10.1016/j.coph.2009.11.005

16. Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, et al. The role of NETs in atherothrombosis: a potential therapeutic target. Circ Res. (2011) 109:374–81. doi: 10.1161/CIRCRESAHA.111.256438

17. Balbi GS, Lioi MC, Torigian DA, Sirota VM, Martorana AE, et al. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-kB. Arterioscler Thromb Vasc Biol. (2011) 31:2733–41. doi: 10.1161/ATVBAHA.111.3302571

18. Perry HM, Oldham SN, Fahl SP, Que X, Gonen A, Harmon DB, et al. Protective role for B1b B cells and IgM in obesity-associated inflammation, and its receptor CCR6. Curr Opin Immunol. (2019) 63:186–94. doi: 10.1016/j.coi.2019.07.007

31. Ruth JH, Shahrara S, Park CC, Morel JC, Kumar P, Qin S, et al. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest. (2003) 83:579–88. doi: 10.1097/01.LAB.0000062854.30195.52

32. Bowman EP, Campbell JL, Soler D, Dong Z, Manlongat N, Picarella D, et al. Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med. (2000) 191:1303–18. doi: 10.1084/jem.191.8.13003

33. Krzyziek R, Lefevre EA, Bernard J, Foussat A, Galanaud P, Louache F, et al. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood. (2000) 96:2338–45. doi: 10.1182/blood.V9.6.2338

34. Liao F, Rubin RL, Smith CS, Sharma G, Nutman TB, Farber JM. CCR6 promotes B-1 cell-mediated atheroprotection and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol. (1999) 162:186–94.
48. Cherepanova OA, Srikakulapu P, Greene ES, Chaklader M, Haskins RM, McCanna ME, et al. Novel autoimmune IgM antibody attenuates atherosclerosis in IgM deficient low-fat diet-fed, but not western diet-Fed ApoE−/− mice. Arterioscler Thromb Vasc Biol. (2020) 40:206–19. doi: 10.1161/ATVBAHA.119.312771

49. Chen Y, Park YB, Patel E, Silverman GJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol. (2009) 182:6031–43. doi: 10.4049/jimmunol.0804191

50. Litvack ML, Post M, Palaniyar N. IgM promotes the clearance of small particles and apoptotic microparticles by macrophages. PLoS ONE. (2011) 6:e17223. doi: 10.1371/journal.pone.0017223

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Srikakulapu, Upadhye, Drago, Perry, Bontha, McSkimming, Marshall, Taylor and McNamara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.